[1]Mazieres J, Paik P K, Garassino M C, et al. Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial[J]. JAMA Oncology, 2023.
[2]Paik P K, Felip E, Veillon R, et al. Tepotinib in non–small-cell lung cancer with MET exon 14 skipping mutations[J]. New England Journal of Medicine, 2020, 383(10): 931-943.